• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

Generation of two human induced pluripotent stem cell lines from fibroblasts of unrelated Parkinson's patients carrying the G2019S mutation in the LRRK2 gene (LCSBi005, LCSBi006).

作者信息

Novak Gabriela, Finkbeiner Steven, Skibinski Gaia, Skupin Alexander

机构信息

The Integrative Cell Signaling Group, Luxembourg Centre for Systems Biomedicine (LCSB), University of Luxembourg, Esch-sur-Alzette, Luxembourg; Gladstone Center for Systems and Therapeutics, Gladstone Institutes and Departments of Neurology and Physiology, University of California, San Francisco San Francisco, CA 94158, USA.

Gladstone Center for Systems and Therapeutics, Gladstone Institutes and Departments of Neurology and Physiology, University of California, San Francisco San Francisco, CA 94158, USA.

出版信息

Stem Cell Res. 2021 Dec;57:102569. doi: 10.1016/j.scr.2021.102569. Epub 2021 Oct 12.

DOI:10.1016/j.scr.2021.102569
PMID:34736041
Abstract

Mutations in the LRRK2 gene are known to mediate predisposition to Parkinson disease. Fibroblasts heterozygous for the G2019S LRRK2 mutation were obtained from a 53-year-old male patient with disease onset at 34 years (LCSBi005, ND29542), and from a 63-year-old male patient with disease onset at 56 years (LCSBi006, ND34267). Induced pluripotent stem cell (iPSC) clones were generated for each cell line using Sendai virus. The absence of chromosomal defects was confirmed using array comparative genomic hybridization. The cell lines express pluripotency markers and have the ability to differentiate into all three germ layers.

摘要

相似文献

1
Generation of two human induced pluripotent stem cell lines from fibroblasts of unrelated Parkinson's patients carrying the G2019S mutation in the LRRK2 gene (LCSBi005, LCSBi006).
Stem Cell Res. 2021 Dec;57:102569. doi: 10.1016/j.scr.2021.102569. Epub 2021 Oct 12.
2
Generation and characterization of induced pluripotent stem cells from a Parkinson's disease patient carrying the digenic LRRK2 p.G2019S and GBA1 p.N409S mutations.从携带双基因突变 LRRK2 p.G2019S 和 GBA1 p.N409S 的帕金森病患者中诱导多能干细胞的产生和特性鉴定。
Stem Cell Res. 2023 Oct;72:103212. doi: 10.1016/j.scr.2023.103212. Epub 2023 Sep 28.
3
Generation of an induced pluripotent stem cell line (CSC-41) from a Parkinson's disease patient carrying a p.G2019S mutation in the LRRK2 gene.从一名在亮氨酸丰富重复激酶 2(LRRK2)基因中携带 p.G2019S 突变的帕金森病患者身上生成诱导多能干细胞系(CSC-41)。
Stem Cell Res. 2018 Apr;28:44-47. doi: 10.1016/j.scr.2018.01.022. Epub 2018 Feb 2.
4
Generation of an induced pluripotent stem cell line (DANi-011A) from a Parkinson's disease patient with a LRRK2 p.G2019S mutation.从一名携带LRRK2 p.G2019S突变的帕金森病患者中生成诱导多能干细胞系(DANi-011A)。
Stem Cell Res. 2020 May;45:101781. doi: 10.1016/j.scr.2020.101781. Epub 2020 Mar 29.
5
In vitro genome editing rescues parkinsonism phenotypes in induced pluripotent stem cells-derived dopaminergic neurons carrying LRRK2 p.G2019S mutation.体外基因编辑挽救了携带 LRRK2 p.G2019S 突变的诱导多能干细胞衍生的多巴胺能神经元帕金森病表型。
Stem Cell Res Ther. 2021 Sep 22;12(1):508. doi: 10.1186/s13287-021-02585-2.
6
Generation of 2 induced pluripotent stem cell lines derived from patients with Parkinson's disease carrying LRRK2 G2385R variant.源自携带LRRK2 G2385R变异的帕金森病患者的2个诱导多能干细胞系的产生。
Stem Cell Res. 2018 Apr;28:1-5. doi: 10.1016/j.scr.2018.01.034. Epub 2018 Feb 28.
7
LRRK2 kinase inhibitors reduce alpha-synuclein in human neuronal cell lines with the G2019S mutation.LRRK2 激酶抑制剂可降低携 G2019S 突变的人神经元细胞系中的α-突触核蛋白。
Neurobiol Dis. 2020 Oct;144:105049. doi: 10.1016/j.nbd.2020.105049. Epub 2020 Aug 13.
8
LRRK2 mutations cause mitochondrial DNA damage in iPSC-derived neural cells from Parkinson's disease patients: reversal by gene correction.LRRK2 突变导致帕金森病患者 iPSC 衍生神经细胞中线粒体 DNA 损伤:基因矫正可逆转。
Neurobiol Dis. 2014 Feb;62:381-6. doi: 10.1016/j.nbd.2013.10.013. Epub 2013 Oct 19.
9
Generation of Parkinson's disease patient-derived human induced pluripotent stem cells line (PNUSCRi001-A) carrying a N227S mutation in GBA gene.携带GBA基因N227S突变的帕金森病患者来源的人诱导多能干细胞系(PNUSCRi001-A)的生成。
Stem Cell Res. 2022 Dec;65:102959. doi: 10.1016/j.scr.2022.102959. Epub 2022 Oct 31.
10
Phenotypical Differences in Neuronal Cultures Derived via Reprogramming the Fibroblasts from Patients Carrying Mutations in Parkinsonian Genes LRRK2 and PARK2.通过重编程携带帕金森病相关基因LRRK2和PARK2突变的患者的成纤维细胞所获得的神经元培养物中的表型差异。
Bull Exp Biol Med. 2015 Oct;159(6):772-5. doi: 10.1007/s10517-015-3072-9. Epub 2015 Oct 31.

引用本文的文献

1
Generation of two human induced pluripotent stem cell lines (iPSCs) with mutations of the α-synuclein (SNCA) gene associated with Parkinson's disease; the A53T mutation (LCSBi003) and a triplication of the SNCA gene (LCSBi007).生成了两条携带与帕金森病相关的α-突触核蛋白(SNCA)基因突变的人诱导多能干细胞系(iPSC);A53T突变(LCSBi003)和SNCA基因三倍体(LCSBi007)。
Stem Cell Res. 2021 Dec;57:102600. doi: 10.1016/j.scr.2021.102600. Epub 2021 Nov 22.